A Glimpse Into The Expert Outlook On Vertex Through 7 Analysts

Ratings for Vertex (NASDAQ: VERX) were provided by 7 analysts in the past three months, showcasing a mix of bullish and ...

Vertex Pharmaceuticals: Trikafta And Alyftrek Cement Market Leadership

Vertex's revenue was $2.96 billion in the second quarter of 2025, beating the consensus forecast by $58 million. Click here ...
The Motley Fool

1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals

Vertex Pharmaceuticals has a lot of buy and hold ratings, but there aren't any sell ratings from Wall Street analysts. Around 75,000 people with cystic fibrosis rely on Vertex Pharmaceuticals to keep ...
The Pharma Letter

Vertex predicted to remain front and center of modest CF market growth

The cystic fibrosis (CF) market in the seven major markets (7MM) is forecast to grow from $11.1 billion in 2024 to $16 billion in 2034, growing at a modest compound annual growth rate (CAGR) of 3.8%, ...